Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 3Neuroblastoma 3Recurrence 2Neoplasms 2Melanoma 2Glioma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Medulloblastoma 1Lymphoma 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinosarcoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Advanced or Metastatic ER+ Breast Cancer 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 8Radiotherapy 7Fluorouracil 6Neoadjuvant Therapy 4Irinotecan 4pembrolizumab 3Paclitaxel 3Gefitinib 3Carboplatin 3toripalimab 2spartalizumab 2Oxaliplatin 2Nivolumab 2Esophagectomy 2Docetaxel 2vandetanib 1tislelizumab 1sitravatinib 1ribociclib 1oblimersen 1nazartinib 1liposomal doxorubicin 1apatinib 1Surgical Procedures, Operative 1SGN-LIV1A 1Proton Therapy 1Pemetrexed 1Panitumumab 1Nutritional Support 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Esophageal Squamous Cell Carcinoma × ribociclib × Clear all
NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Novartis

Phase 1 Terminated
122 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡